{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:54:55Z","timestamp":1784735695608,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"2022 Anhui Medical University Clinical Medicine Discipline Development Project","award":["9301001813"],"award-info":[{"award-number":["9301001813"]}]},{"name":"Anhui Medical University Discipline Development Project for 2023"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02571-x","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T07:00:57Z","timestamp":1745650857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Meta-analysis on the effectiveness and safety of venetoclax-based combination therapy with hypomethylation in acute myeloid leukemia"],"prefix":"10.1186","volume":"30","author":[{"given":"Yi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongdong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengbo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leiming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"issue":"12","key":"2571_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136\u201352.","journal-title":"N Engl J Med"},{"key":"2571_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"issue":"1","key":"2571_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","volume":"17","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17(1):13\u201327.","journal-title":"Cancer Cell"},{"issue":"22","key":"2571_CR4","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ Jr, Laird PW, Baty JD, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374.","journal-title":"N Engl J Med"},{"issue":"20","key":"2571_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"23","key":"2571_CR6","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"2571_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"7","key":"2571_CR8","doi-asserted-by":"publisher","first-page":"926","DOI":"10.6004\/jnccn.2017.0116","volume":"15","author":"MR O'Donnell","year":"2017","unstructured":"O\u2019Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, et al. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(7):926\u201357.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"2571_CR9","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/0092-8674(93)90325-K","volume":"75","author":"SD Lyman","year":"1993","unstructured":"Lyman SD, James L, Vanden Bos T, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR, et al. Molecular cloning of a ligand for the flt3\/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell. 1993;75(6):1157\u201367.","journal-title":"Cell"},{"issue":"2","key":"2571_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1073\/pnas.91.2.459","volume":"91","author":"D Small","year":"1994","unstructured":"Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, Witte L, Burrow C, Ratajczak MZ, Gewirtz AM, et al. STK-1, the human homolog of Flk-2\/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor\/stem cells. Proc Natl Acad Sci U S A. 1994;91(2):459\u201363.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"2571_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3109\/10428199909093728","volume":"33","author":"HG Drexler","year":"1999","unstructured":"Drexler HG, Meyer C, Quentmeier H. Effects of FLT3 ligand on proliferation and survival of myeloid leukemia cells. Leuk Lymphoma. 1999;33(1\u20132):83\u201391.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2571_CR12","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","volume":"100","author":"DG Gilliland","year":"2002","unstructured":"Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5):1532\u201342.","journal-title":"Blood"},{"issue":"2","key":"2571_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299\u2013312.","journal-title":"Leukemia"},{"issue":"6","key":"2571_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18(6):553\u201367.","journal-title":"Cancer Cell"},{"issue":"6","key":"2571_CR15","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1001\/jamaoncol.2015.0617","volume":"1","author":"TM Kadia","year":"2015","unstructured":"Kadia TM, Ravandi F, Cortes J, Kantarjian H. Toward Individualized therapy in acute myeloid leukemia: a contemporary review. JAMA Oncol. 2015;1(6):820\u20138.","journal-title":"JAMA Oncol"},{"issue":"3","key":"2571_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clml.2014.08.006","volume":"15","author":"TM Kadia","year":"2015","unstructured":"Kadia TM, Ravandi F, O\u2019Brien S, Cortes J, Kantarjian HM. Progress in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15(3):139\u201351.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2571_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/ajh.24246","volume":"91","author":"H Kantarjian","year":"2016","unstructured":"Kantarjian H. Acute myeloid leukemia\u2013major progress over four decades and glimpses into the future. Am J Hematol. 2016;91(1):131\u201345.","journal-title":"Am J Hematol"},{"issue":"10147","key":"2571_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","volume":"392","author":"NJ Short","year":"2018","unstructured":"Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593\u2013606.","journal-title":"Lancet"},{"issue":"1","key":"2571_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","volume":"127","author":"H Dombret","year":"2016","unstructured":"Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53\u201361.","journal-title":"Blood"},{"issue":"3","key":"2571_CR20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","volume":"18","author":"P Bose","year":"2017","unstructured":"Bose P, Vachhani P, Cortes JE. Treatment of relapsed\/refractory acute myeloid leukemia. Curr Treat Options Oncol. 2017;18(3):17.","journal-title":"Curr Treat Options Oncol"},{"key":"2571_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.12.004","volume":"110","author":"G Tamamyan","year":"2017","unstructured":"Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, Daver N, Ohanian M, Kantarjian H, Konopleva M. Frontline treatment of acute myeloid leukemia in adults. Crit Rev Oncol Hematol. 2017;110:20\u201334.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"2571_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"H Liu","year":"2021","unstructured":"Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021;14(1):49.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2571_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1358\/dot.2016.52.4.2470954","volume":"52","author":"G Del Poeta","year":"2016","unstructured":"Del Poeta G, Postorino M, Pupo L, Del Principe MI, Dal Bo M, Bittolo T, Buccisano F, Mariotti B, Iannella E, Maurillo L, et al. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia. Drugs Today (Barc). 2016;52(4):249\u201360.","journal-title":"Drugs Today (Barc)"},{"key":"2571_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101195","volume":"65","author":"DJ Fowler-Shorten","year":"2024","unstructured":"Fowler-Shorten DJ, Hellmich C, Markham M, Bowles KM, Rushworth SA. BCL-2 inhibition in haematological malignancies: clinical application and complications. Blood Rev. 2024;65: 101195.","journal-title":"Blood Rev"},{"issue":"10","key":"2571_CR25","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, McKeegan E, Salem AH, Zhu M, Ricker JL, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106\u201317.","journal-title":"Cancer Discov"},{"issue":"4","key":"2571_CR26","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, Kipps TJ, Anderson MA, Brown JR, Gressick L, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"6","key":"2571_CR27","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","volume":"17","author":"S Stilgenbauer","year":"2016","unstructured":"Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768\u201378.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2571_CR28","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/10428194.2014.910657","volume":"56","author":"JM Bogenberger","year":"2015","unstructured":"Bogenberger JM, Delman D, Hansen N, Valdez R, Fauble V, Mesa RA, Tibes R. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma. 2015;56(1):226\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2571_CR29","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg (London, England). 2010;8(5):336\u201341.","journal-title":"Int J Surg (London, England)"},{"key":"2571_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed). 2011;343: d5928.","journal-title":"BMJ (Clinical research ed)"},{"issue":"9","key":"2571_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135.","journal-title":"Eur J Epidemiol"},{"issue":"9","key":"2571_CR32","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136.","journal-title":"ANZ J Surg"},{"issue":"2","key":"2571_CR33","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","volume":"19","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018;19(2):216\u201328.","journal-title":"Lancet Oncol"},{"issue":"20","key":"2571_CR34","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","volume":"3","author":"AC Winters","year":"2019","unstructured":"Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3(20):2911\u20139.","journal-title":"Blood Adv"},{"issue":"9","key":"2571_CR35","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/ajh.25859","volume":"95","author":"M Byrne","year":"2020","unstructured":"Byrne M, Danielson N, Sengsayadeth S, Rasche A, Culos K, Gatwood K, Wyatt H, Chinratanalab W, Dholaria B, Ferrell PB, et al. The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia. Am J Hematol. 2020;95(9):1006\u201314.","journal-title":"Am J Hematol"},{"issue":"7","key":"2571_CR36","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, D\u00f6hner H, Letai A, Fenaux P, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617\u201329.","journal-title":"N Engl J Med"},{"key":"2571_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106317","volume":"91","author":"Y Lou","year":"2020","unstructured":"Lou Y, Shao L, Mao L, Lu Y, Ma Y, Fan C, Jiang H, Li J, Jin J. Efficacy and predictive factors of venetoclax combined with azacitidine as salvage therapy in advanced acute myeloid leukemia patients: a multicenter retrospective study. Leuk Res. 2020;91: 106317.","journal-title":"Leuk Res"},{"issue":"24","key":"2571_CR38","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","volume":"5","author":"EM Cherry","year":"2021","unstructured":"Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5(24):5565\u201373.","journal-title":"Blood Adv"},{"issue":"3","key":"2571_CR39","first-page":"290","volume":"11","author":"S Mirgh","year":"2021","unstructured":"Mirgh S, Sharma A, Shaikh M, Kadian K, Agrawal N, Khushoo V, Mehta P, Ahmed R, Bhurani D. Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy\u2014novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country. Am J Blood Res. 2021;11(3):290\u2013302.","journal-title":"Am J Blood Res"},{"issue":"2","key":"2571_CR40","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajh.26039","volume":"96","author":"DA Pollyea","year":"2021","unstructured":"Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, Konopleva M, Thirman MJ, Arellano M, Becker PS, et al. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Am J Hematol. 2021;96(2):208\u201317.","journal-title":"Am J Hematol"},{"issue":"21","key":"2571_CR41","first-page":"6557","volume":"25","author":"MA Ucar","year":"2021","unstructured":"Ucar MA, Ozet G, Koyuncu MB, Sonmez M, Akidan O, Ayli M, Yildirim M, Pehlivan M, Akkurd DM, Sahin H, et al. Real world results of venetoclax combined with hypomethylating agents in relapsed\/refractory AML. Eur Rev Med Pharmacol Sci. 2021;25(21):6557\u201365.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2571_CR42","doi-asserted-by":"crossref","unstructured":"Garciaz S, Hospital MA, Alary AS, Saillard C, Hicheri Y, Mohty B, Rey J, D'Incan E, Charbonnier A, Villetard F et al. Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients. Cancers (Basel). 2022; 14(8).","DOI":"10.3390\/cancers14082025"},{"issue":"13","key":"2571_CR43","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","volume":"6","author":"AH Matthews","year":"2022","unstructured":"Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL, Babushok DV, Maillard IP, Carroll MP, Frey NV, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;6(13):3997\u20134005.","journal-title":"Blood Adv"},{"issue":"6","key":"2571_CR44","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1111\/bjh.17996","volume":"196","author":"A Salhotra","year":"2022","unstructured":"Salhotra A, Tsai NC, Zhang J, Ngo D, Aribi A, Sandhu K, Ball B, Al-Malki M, Ali H, Koller P, et al. Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia. Br J Haematol. 2022;196(6):e71\u20134.","journal-title":"Br J Haematol"},{"key":"2571_CR45","doi-asserted-by":"crossref","unstructured":"Wang W, Luo Q, Chen Q, Pang A, Fang K. Analysis of the clinical efficacy of azacytidine + venetoclax in the treatment of elderly patients with relapsed refractory acute myeloid leukemia. Evid-Based Complement Alternat Med. 2022; 2022.","DOI":"10.1155\/2022\/8691835"},{"issue":"3","key":"2571_CR46","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","volume":"102","author":"M Aiba","year":"2023","unstructured":"Aiba M, Shigematsu A, Suzuki T, Miyagishima T. Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia. Ann Hematol. 2023;102(3):541\u20136.","journal-title":"Ann Hematol"},{"issue":"1","key":"2571_CR47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.14740\/wjon1557","volume":"14","author":"T Freeman","year":"2023","unstructured":"Freeman T, Williams K, Puto M, Waller A, McLaughlin EM, Blachly JS, Roddy J. Real-world experience of adults with acute myeloid leukemia on hypomethylating agents with or without venetoclax at a comprehensive cancer center. World J Oncol. 2023;14(1):40\u201350.","journal-title":"World J Oncol"},{"key":"2571_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4274\/tjh.galenos.2023.2023.0089","volume":"40","author":"H G\u00f6ker","year":"2023","unstructured":"G\u00f6ker H, \u00c7\u0131nar OE, Demiro\u011flu H, Malkan \u00dcY, Alada\u011f Karakulak E, B\u00fcy\u00fcka\u015f\u0131k Y. Venetoclax and azacitidine treatment in relapsed acute myeloid leukemia after hematopoietic stem cell transplantation: a cohort study in a tertiary center real-world setting. Turk J Haematol. 2023;40:213.","journal-title":"Turk J Haematol"},{"issue":"6","key":"2571_CR49","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/10428194.2023.2197090","volume":"64","author":"FW Hoff","year":"2023","unstructured":"Hoff FW, Patel PA, Belli AJ, Hansen E, Foss H, Schulte M, Wang CK, Madanat YF. Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data. Leuk Lymphoma. 2023;64(6):1123\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2571_CR50","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/CAD.0000000000001431","volume":"34","author":"RH Hu","year":"2023","unstructured":"Hu RH, Su L, Lan XX, Chang XL, Hui WH, Guo YX, Zhao H, Zhang Y, Sun WL. A retrospective assessment of real-world experience with venetoclax and azacitidine therapy in elderly acute myeloid leukemia. Anticancer Drugs. 2023;34(3):344\u201350.","journal-title":"Anticancer Drugs"},{"issue":"6","key":"2571_CR51","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.1002\/cam4.5459","volume":"12","author":"L Laloi","year":"2023","unstructured":"Laloi L, Billotey NC, Dumas PY, Paul F, Villate A, Simand C, Fornecker L, Puisset F, Bertoli S, Simonet MB, et al. Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy. Cancer Med. 2023;12(6):7175\u201381.","journal-title":"Cancer Med"},{"issue":"1","key":"2571_CR52","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-023-01394-8","volume":"8","author":"L Xia","year":"2023","unstructured":"Xia L, Tian W, Zhao Y, Jiang L, Qian W, Jiang L, Ge L, Li J, Jin F, Yang M. Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy. Signal Transduct Target Ther. 2023;8(1):176.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2571_CR53","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/jpm11060463","volume":"11","author":"M Lasica","year":"2021","unstructured":"Lasica M, Anderson MA. Review of venetoclax in CLL, AML and multiple myeloma. J Pers Med. 2021;11(6):463.","journal-title":"J Pers Med"},{"issue":"5","key":"2571_CR54","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","volume":"34","author":"CL Jones","year":"2018","unstructured":"Jones CL, Stevens BM, D\u2019Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, et al. Inhibition of amino acid metabolism selectively targets human leukemia stem cells. Cancer Cell. 2018;34(5):724-740.e724.","journal-title":"Cancer Cell"},{"issue":"Supplement 1","key":"2571_CR55","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood-2018-99-117179","volume":"132","author":"DA Pollyea","year":"2018","unstructured":"Pollyea DA, Pratz KW, Jonas BA, Letai A, Pullarkat VA, Wei A, Konopleva MY, Recher C, Frankfurt O, Rizzieri D, et al. Venetoclax in combination with hypomethylating agents induces rapid, deep, and durable responses in patients with AML ineligible for intensive therapy. Blood. 2018;132(Supplement 1):285\u2013285.","journal-title":"Blood"},{"issue":"1","key":"2571_CR56","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1186\/s12885-020-07331-0","volume":"20","author":"C Guo","year":"2020","unstructured":"Guo C, Gao YY, Ju QQ, Zhang CX, Gong M, Li ZL. LINC00649 underexpression is an adverse prognostic marker in acute myeloid leukemia. BMC Cancer. 2020;20(1):841.","journal-title":"BMC Cancer"},{"issue":"1","key":"2571_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11899-017-0363-4","volume":"12","author":"C Gardin","year":"2017","unstructured":"Gardin C, Dombret H. Hypomethylating agents as a therapy for AML. Curr Hematol Malig Rep. 2017;12(1):1\u201310.","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"2571_CR58","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","volume":"4","author":"CA Lachowiez","year":"2020","unstructured":"Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, et al. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020;4(7):1311\u201320.","journal-title":"Blood Adv"},{"issue":"9","key":"2571_CR59","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1182\/blood-2016-07-730648","volume":"129","author":"S Knapper","year":"2017","unstructured":"Knapper S, Russell N, Gilkes A, Hills RK, Gale RE, Cavenagh JD, Jones G, Kjeldsen L, Grunwald MR, Thomas I, et al. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood. 2017;129(9):1143\u201354.","journal-title":"Blood"},{"issue":"12","key":"2571_CR60","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1007\/s00277-019-03795-8","volume":"98","author":"T Berger","year":"2019","unstructured":"Berger T, Rozovski U, Moshe Y, Yaari S, Frisch A, Hellmann I, Apel A, Aviram A, Koren-Michowitz M, Yeshurun M, et al. Midostaurin in combination with intensive chemotherapy is safe and associated with improved remission rates and higher transplantation rates in first remission-a multi-center historical control study. Ann Hematol. 2019;98(12):2711\u20137.","journal-title":"Ann Hematol"},{"issue":"11","key":"2571_CR61","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","volume":"22","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi AT, Kantarjian HM, Bennett JM, et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 2021;22(11):1597\u2013608.","journal-title":"Lancet Oncol"},{"issue":"16","key":"2571_CR62","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, Heuser M, Calado RT, Schuh AC, Yeh SP, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386(16):1519\u201331.","journal-title":"N Engl J Med"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02571-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T08:02:51Z","timestamp":1745654571000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02571-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2571"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02571-x","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"330"}}